Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gepirone - Fabre-Kramer Pharmaceuticals

X
Drug Profile

Gepirone - Fabre-Kramer Pharmaceuticals

Alternative Names: Ariza; BMY 13805-1; BMY-13805; EXXUA; Gepirone ER - Fabre-Kramer Pharmaceuticals; Gepirone extended release - Fabre-Kramer Pharmaceuticals; Gepirone hydrochloride extended-release - Fabre-Kramer Pharmaceuticals; MJ-13805; Org-33062; TGFK07AD; Travivo™; Variza™

Latest Information Update: 05 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Fabre-Kramer Pharmaceuticals
  • Class Antidepressants; Anxiolytics; Ketones; Piperazines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Decreased libido; Generalised anxiety disorder

Highest Development Phases

  • Registered Major depressive disorder
  • Phase III Decreased libido; Generalised anxiety disorder
  • Discontinued Cocaine-related disorders

Most Recent Events

  • 05 Oct 2023 Gepirone is available for licensing as of 05 Oct 2023. https://fabrekramer.com/ (Fabre-Kramer Pharmaceuticals website, October 2023).
  • 05 Oct 2023 Chemical structure information added for salt form of the drug
  • 05 Oct 2023 Phase-III clinical trials in Decreased libido (PO, Controlled release) prior to October 2023 (Fabre-Kramer Pharmaceuticals website, October 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top